Hepatitis C Virus(HCV) Heart and Lung Study



Status:Recruiting
Conditions:Chronic Obstructive Pulmonary Disease, Cardiology, Pulmonary, Pulmonary, Hepatitis, Hepatitis, Hepatitis
Therapuetic Areas:Cardiology / Vascular Diseases, Immunology / Infectious Diseases, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - Any
Updated:12/22/2018
Start Date:December 2016
End Date:April 2019
Contact:Lori Hudson, PhD
Email:lori.hudson@duke.edu
Phone:919-259-5579

Use our guide to learn which trials are right for you!

A Multicenter, Open-label Study of Harvoni ® (Sofosbuvir Ledipasvir Fixed Dose Combination) in Subjects Infected With Chronic Hepatitis C and Advanced Heart Failure or Lung Disease

This is a multicenter study in Hepatitis C Virus (HCV) infected adult patients who also have
advanced cardiac disease or advanced lung disease.

This is a multicenter study in HCV infected adult patients who also have either advanced
cardiac disease, or advanced lung disease. Advanced cardiac disease is defined as a marked
limitation of physical activity, or discomfort upon physical activity. The patients in the
advanced cardiac disease group must also have been hospitalized for heart failure within the
last 12 months.

Advanced lung disease is defined as patients who have been diagnosed with chronic obstructive
pulmonary disease (COPD) or interstitial lung disease (ILD). Patients in the COPD group must
have abnormalities in their forced expiratory volume (FEV) test, which measures the amount of
air exhaled. They may or may not need supplemental oxygen. Patients in the ILD group must
have been diagnosed with ILD and require supplement oxygen at all times.

Inclusion Criteria:

- Chronic HCV Infection of Genotype 1, 4, 5, or 6

- HCV RNA > 103 IU/mL at screening

- 18 years of age or older

- Diagnosis of chronic HCV infection, defined as positive HCV antibody or HCV RNA more
than 6 months prior to screening OR an assessment of fibrosis F2 or greater prior to
screening.

Subjects in the advanced heart failure cohort must meet all HCV criteria, and all of the
following criteria:

- New York Heart Association (NYHA) Class III or IV functional classification

- NYHA Class III: Subjects with cardiac disease resulting in marked limitation of
physical activity. They are comfortable at rest. Less than ordinary physical
activity causes fatigue, palpitation, dyspnea, or anginal pain.

- NYHA Class IV: Patient with cardiac disease resulting in inability to carry on
any physical activity without discomfort. Symptoms of cardiac insufficiency or of
the anginal syndrome may be present even at rest. If any physical activity is
undertaken, discomfort is increased.

- ejection fraction ≤ 30%

- hospitalized for heart failure in last 12 months

Subjects in the advanced lung disease cohort must have been diagnosed with chronic
obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) must meet all HCV
criteria, and meet the following criteria for COPD or ILD:

- ILD criteria: diagnosis of interstitial lung disease with chronic supplemental oxygen
requirement at rest and/or with exertion.

- COPD criteria (one of the following):

- Forced expiratory volume (FEV1)< 30% predicted

- OR any FEV1 with chronic supplemental oxygen requirement at rest and/or with
exertion

- OR any FEV1 with chronic hypercapnia (baseline partial pressure of arterial
carbon dioxide [PaCO2] > 45)

Exclusion Criteria:

- Chronic HCV Infection with Genotype 2 or 3

- Treatment with any of the following agents

- Amiodarone. Subjects previously treated with amiodarone must have stopped the
amiodarone at least 60 days prior to day 1 of SOF/LDV FDC

- Carbamazepine, phenytoin, phenobarbital, oxcarbazepine

- Rifabutin, rifampin or rifapentine

- HIV regimens containing tenofovir or tipranavir/ritonavir

- St. John's wort

- Rosuvastatin

- Have any serious or active medical or psychiatric illness which, in the opinion of the
investigator, would interfere with subject treatment, assessment, or compliance

- History of hepatic encephalopathy or variceal hemorrhage

- Hepatitis B surface antigen positive

- Abnormal hematological and biochemical parameters, including:

- Hemoglobin (Hb) < 8 g/dL

- Platelets ≤ 50,000/mm3

- alanine aminotransferase (ALT), aspartase aminotransferase (AST), or alkaline
phosphatase ≥ 10 times upper limit of normal(ULN)

- Total bilirubin > 3 mg/dl

- Severe renal impairment creatinine clearance (CrCl), i.e. < 30 mL/min.

- History of major organ transplantation with an existing functional graft.

- History of clinically-significant drug allergy to nucleoside/nucleotide analogs.

- Pregnant women or women planning to become pregnant

- Women who are breastfeeding

- Active or recent history (≤ 1 year) of drug or alcohol abuse
We found this trial at
4
sites
Detroit, Michigan 48202
Principal Investigator: Gordon Stuart, MD
Phone: 313-916-8423
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Durham, North Carolina 27705
Principal Investigator: Julius Wilder, MD
?
mi
from
Durham, NC
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Principal Investigator: Elizabeth Verna, MD
Phone: 212-305-1877
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
325 9th Ave
Seattle, Washington 98104
(206) 744-3300
Principal Investigator: Charles Landis, MD
Phone: 206-744-2341
Harborview Medical Center Harborview Medical Center is the only designated Level 1 adult and pediatric...
?
mi
from
Seattle, WA
Click here to add this to my saved trials